EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Association of Nirmatrelvir/Ritonavir and the Risk of Long COVID Among US Adults: A Multicenter Retrospective Cohort Study

Chun-Tse Hung iD, Li-Min Wang, Yuarn-Jang Lee, Chi-Won Suk, Chin-Yee Kok

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70494 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Chun-Tse Hung und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Ritonavir, COVID-19 Drug Treatment, Antiviral Agents, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nirmatrelvir/ritonavir (NMV‐r) is an oral antiviral agent authorized for treating acute COVID‐19, but its effectiveness in reducing long COVID risk remains uncertain. This multicenter retrospective cohort study aimed to evaluate the association between NMV‐r and the risk of long COVID. Electronic health record data from the TriNetX US Collaborative Network were used. Adults aged ≥ 18 years with a positive COVID‐19 test between January 1, 2022 and June 30, 2024 were included. NMV‐r users were those who received NMV‐r within 5 days of testing positive, while those who did not receive NMV‐r within this period were the nonusers. The outcome was time to the first diagnosis of incident post‐COVID conditions, including general, pulmonary, cardiac, thromboembolic, neurologic, mental, musculoskeletal, gastrointestinal, and kidney symptoms. Propensity score matching was performed to balance baseline characteristics and Cox proportional hazards models were used to estimate the risk of long COVID between NMV‐r users and nonusers. Both groups included 218 825 patients after matching. Overall, the risk of long COVID was similar between NMV‐r users and nonusers (HR, 0.99; 95% CI, 0.98–1.01). Symptom‐specific analyses revealed mixed effects, with NMV‐r use associated with an increased risk of cough and sleeping disorders but a decreased risk for other long COVID symptoms. Sensitivity analyses showed consistent results with the main analysis. In conclusion, NMV‐r use was not associated with a reduced risk of long COVID. Future research is needed to explore its heterogeneous effects on post‐COVID conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirCOVID-19 Drug TreatmentAntiviral AgentsCOVID-19HumansRetrospective StudiesMaleFemaleMiddle AgedAdultAgedUnited StatesSARS-CoV-2

Stichwörter der Autor:innen

COVID‐19long COVIDnirmatrelvirnirmatrelvir/ritonavirpostacute sequelae of COVID‐19post‐COVID conditions

Substanzen

RitonavirAntiviral Agents

Autor:innen und Institutionen

  • School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Department of Pharmacy, Taipei Medical University Hospital, Taipei, Taiwan.
  • Department of Internal Medicine, Division of Infectious Diseases, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.
  • Department of Internal Medicine, School of Medicine, Division of Infectious Diseases, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Department of Internal Medicine, Division of Pulmonary Medicine, Taipei Municipal Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Chun-Tse Hung

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Hung, C. T., Wang, L. M., Lee, Y. J., Suk, C. W., & Kok, C. Y. (2025). Association of Nirmatrelvir/Ritonavir and the Risk of Long COVID Among US Adults: A Multicenter Retrospective Cohort Study. Journal of Medical Virology. https://doi.org/10.1002/jmv.70494

Vancouver

Hung CT, Wang LM, Lee YJ, Suk CW, Kok CY. Association of Nirmatrelvir/Ritonavir and the Risk of Long COVID Among US Adults: A Multicenter Retrospective Cohort Study. Journal of Medical Virology. 2025. doi:10.1002/jmv.70494

BibTeX
@article{Hung2025,
  author = {Hung, Chun-Tse and Wang, Li-Min and Lee, Yuarn-Jang and Suk, Chi-Won and Kok, Chin-Yee},
  title = {Association of Nirmatrelvir/Ritonavir and the Risk of Long COVID Among US Adults: A Multicenter Retrospective Cohort Study},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70494}
}
Kostenlos starten →